An announcement from Telomir Pharmaceuticals, Inc. ( (TELO) ) is now available.
Telomir Pharmaceuticals announced preclinical data showing that its lead oral drug candidate, Telomir-1, can reverse key drivers of cellular decline in human cell lines. The studies, conducted with SmartAssays, demonstrated improvements in mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects, suggesting potential therapeutic applications for aging and chronic diseases.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a leader in age-reversal science, focusing on developing oral drug candidates that target cellular decline. The company is involved in research initiatives related to autism spectrum disorder and spasmodic dysphonia.
Average Trading Volume: 165,402
Technical Sentiment Signal: Strong Sell
Current Market Cap: $74.7M
See more data about TELO stock on TipRanks’ Stock Analysis page.